Cargando…
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
INTRODUCTION: The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and inhibits the cleavage/activation of human complement component 5 (C5). We present in v...
Autores principales: | Tang, Guo-Qing, Tang, Yalan, Dhamnaskar, Ketki, Hoarty, Michelle D., Vyasamneni, Rohit, Vadysirisack, Douangsone D., Ma, Zhong, Zhu, Nanqun, Wang, Jian-Guo, Bu, Charlie, Cong, Bestine, Palmer, Elizabeth, Duda, Petra W., Sayegh, Camil, Ricardo, Alonso |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446491/ https://www.ncbi.nlm.nih.gov/pubmed/37622108 http://dx.doi.org/10.3389/fimmu.2023.1213920 |
Ejemplares similares
-
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023) -
Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices
por: Muldur, Sinan, et al.
Publicado: (2021) -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
por: Fichtner, Miriam L., et al.
Publicado: (2022) -
Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model
por: Julien, Sarah, et al.
Publicado: (2022) -
Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan
por: Gorman, Declan M., et al.
Publicado: (2021)